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Summary
Background: Allergic rhinitis (AR) management has changed in recent years fol-
lowing the switch from the concept of disease severity to the concept of disease
control, publication of the AR clinical decision support system (CDSS) and devel-
opment of mobile health (m‐health) tools for patients (eg Allergy Diary). The
Allergy Diary Companion app for healthcare providers is currently being developed
and will be launched in 2018. It incorporates the AR CDSS to provide evidence‐
based treatment recommendations, linking all key stakeholders in AR
management.
Objective: To produce an electronic version of the AR CDSS (e‐CDSS) for incorpo-
ration into the Allergy Diary Companion, to describe the app interfaces used to col-
lect information necessary to inform the e‐CDSS and to summarize some key
features of the Allergy Diary Companion.
Methods: The steps involved in producing the e‐CDSS and incorporating it into the
Allergy Diary Companion were (a) generation of treatment management scenarios; (b)
expert consensus on treatment recommendations; (c) generation of electronic deci-
sional algorithms to describe all AR CDSS scenarios; (d) digitization of these algo-
rithms to form the e‐CDSS; and (e) embedding the e‐CDSS into the app to permit
easy user e‐CDSS interfacing.
Results: Key experts in the AR field agreed on the AR CDSS approach to AR man-
agement and on specific treatment recommendations provided by Allergy Diary Com-
panion. Based on this consensus, decision processes were developed and
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programmed into the Allergy Diary Companion using Titanium Appcelerator (Java-
Script) for IOS tablets. To our knowledge, this is the first time the development of
any m‐health tool has been described in this transparent and detailed way,
providing confidence, not only in the app, but also in the provided management
recommendations.
Conclusion: The Allergy Diary Companion for providers provides guideline and
expert‐endorsed AR management recommendations. [MASK paper No 32].
1 | INTRODUCTION
The aim of allergic rhinitis (AR) management is to achieve control
of the disease and its symptoms1,2 and is a dynamic process. Con-
trol can fluctuate over time influenced by many factors, including
AR phenotype (ie intermittent or persistent AR), environmental
exposure and current treatment. Therefore, the tool used to mea-
sure disease control must be simple, suitable for everyday use and
sensitive to change. A simple visual analogue scale (VAS) has been
recommended as the language for assessing AR control.2-4 It has
recently been converted to electronic format and included in a free
mobile app for patients—Allergy Diary—as part of MASK (Mobile
Airways Sentinel network).5-8 The Allergy Diary aims to empower
patients to self‐manage their AR.5,6 The use of self‐management
and information and communication technology may hold the key
to chronic disease management and provides useful objective data
for physicians.
The VAS has also been incorporated into an AR clinical decision
support system (CDSS), a new type of disease management tool.2 A
CDSS is a health information technology system, based on the best
evidence and algorithms, designed to provide physicians, and other
healthcare providers, with clinical decision support (ie assistance with
clinical decision‐making tasks). It is an important tool for precision
medicine.9,10 Within the AR CDSS, the VAS is used to assess AR
control and to assist in making management decisions, assisting
patients and healthcare providers to jointly determine AR treatment
and its step‐up or step‐down strategy depending on the status of AR
control.2
The next step is to integrate the AR CDSS into an app for provi-
ders called Allergy Diary Companion, by producing an electronic ver-
sion of it (e‐CDSS). The Allergy Diary Companion app is designed for
use during a patient‐physician consultation. The e‐CDSS will effec-
tively be the “brain” of the app, providing guideline‐directed AR
management recommendations in response to 4 inputs: VAS score,
Allergic Rhinitis & its Impact on Asthma (ARIA)‐defined AR pheno-
type, allergen exposure and AR treatment history. This article
describes the production of the e‐CDSS from the paper version2 for
incorporation into the Allergy Diary Companion. Expert consensus on
AR CDSS recommendations, as well as the production of decision
processes to describe this consensus and programme the app, is also
described. Finally, description of the various interfaces used by the
app to collect information necessary to inform the e‐CDSS and key
features of Allergy Diary Companion are summarized.
2 | METHODS
Figure 1 outlines the six steps involved in the transformation of the
paper AR CDSS (Figure S1A and B)2 to the e‐CDSS.
2.1 | Step 1: Major scenarios on AR management
approach
Thirteen major scenarios were identified from the AR CDSS (Table
S1). These scenarios incorporated VAS score cut‐offs, ARIA‐defined
AR phenotype (ie intermittent or persistent AR) and AR treatment,
and provided an AR management approach (ie when to initiate treat-
ment, continue, step‐up and step‐down treatment). T0 represents no
treatment. For the purpose of these scenarios, AR treatments were
coded as follows:
• T1: Non-sedating H1-antihistamines (oral, intranasal and intraocu-
lar), leukotriene receptor antagonists (LTRA) and cromones
(intranasal or intraocular)
• T2: Intranasal corticosteroid (INCS)
• T3: INCS + azelastine (AZE)
• T4: Oral corticosteroids (as add on to local treatment)
• T5: Consider referral to an allergist and allergen immunotherapy
(AIT)
The AR CDSS is an algorithm for the acute symptomatic treat-
ment of AR. Recommendations on the benefits and use of AIT may
be found elsewhere.11
2.2 | Step 2: Specific AR treatment
recommendations
From these 13 major scenarios, 34 detailed scenarios were devel-
oped.2 Inputs considered included disease phenotype (ie intermit-
tent/persistent), allergen exposure, VAS score and current
treatment and specific AR management recommendations were
provided (Tables S2-S5).
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2.3 | Step 3: Survey of experts
These 34 detailed scenarios were incorporated into a survey that
was delivered by an online service, Survey Monkey (www.survey
monkey.com), and sent to 70 experts on AR and ARIA members
from 23 countries, in order to achieve consensus and improve
robustness of the AR CDSS algorithm. Experts were selected for
their expertise (ie general practice, allergy, ENT, respiratory medi-
cine, pharmacy and public health) with a global representation. We
aimed at a 50% response rate. The survey was divided into 4 parts:
(a) general approach to AR treatment (ie when to initiate, continue,
step‐up or step‐down treatment; n = 8 questions; Table S2); (b)
treatment step‐up (ie what treatment to step‐up to considering cur-
rent treatment; n = 11 questions; Table S3); (c) treatment step‐
down (ie what treatment to step‐down to considering current treat-
ment; n = 12 questions; Table S4); and (d) treatment initiation (ie
what treatment to start with, considering VAS score and AR phe-
notype; n = 3 questions; Table S5). Experts indicated their level of
agreement for each of the 34 presented scenarios on a VAS rang-
ing from 0 mm (strongly disagree) to 100 mm (strongly agree). A
response was returned by 35 experts (response rate: 50%) from
the USA and Canada (n = 5), Europe (n = 26), South America
(n = 2) and Australia (n = 2).
Individual scores for each of the 34 scenarios were tabulated, aver-
aged and categorized in the classical way: survey VAS score 0‐25 mm
(poor agreement); 25‐49 mm (fair agreement); 50‐74 mm (good agree-
ment); and 75‐100 mm (excellent agreement) (Figure S2A). Excellent
expert consensus was achieved for all step‐up scenarios except scenar-
ios 11 (survey VAS score: 64 mm), 13 (survey VAS score: 64 mm) and
14 (survey VAS score: 64 mm) which all dealt with step‐up from T3
(Table S3; Figure S2A). Excellent expert consensus was also achieved
for all step‐down scenarios except scenarios 20 (survey VAS score:
74 mm) and 21 (survey VAS score: 66 mm) which dealt with
step‐down from T3 or T2, respectively (Table S4; Figure S2A). The
reasons for these lower consensus scores and resolution of these
issues are provided in the online Supporting information.
2.4 | Step 4: Scenario modification and summary of
findings
An email was sent to all experts who provided a survey VAS score
<50 mm for any scenario to (a) understand the reason for
F IGURE 1 Steps for the development of the ARIA e‐CDSS. MACVIA, Contre les Maladies Chroniques pour un Vieillissement actif; ARIA,
Allergic Rhinitis and its Impact on Asthma; AR, allergic rhinitis; CDSS, clinical decision support system; VAS, visual analogue scale; KOL, key
opinion leader
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disagreement and (b) achieve consensus on a resolution. Experts
were permitted to change their original survey VAS scores based on
the results of this discussion process (these changes are shown in
red font in Figure S2B). Expert agreement increased to a VAS score
>75 for all scenarios that were considered a second time. Details of
expert comments on the scenarios, and the response and resolution
are provided in the online Supporting information.
2.5 | Step 5: Digital specifications of AR CDSS (all
scenarios and modifications)
The next step was to digitally specify the agreed scenarios to gener-
ate a series of digital rules used to programme the Allergy Diary Com-
panion (Ecole des Mines, Ales). The first task was to define a set of
representative scenarios with experts of the domain, taking into
account all possible parameters (eg VAS, ongoing treatment and type
of patient). Then, scenarios were translated into a graphical repre-
sentation, providing an algorithm, which allowed the recommenda-
tions to be automatically defined (Figure 2 A‐D). The algorithm was
validated in several ways: (a) review with experts, (b) review of rec-
ommendations and (c) transformation of the algorithm into a state
machine (ie a model representing the state cycle of a patient.) The
process enabled verification that the patient state may evolve,
depending on adequate value of VAS and according to all possible
treatment transitions (ie from “no treatment” to “under treatment”,
staying “under treatment” and come back to “no treatment”). These
verifications ensured that all possible situations were taken into
account in a systematic way.
2.6 | Step 6: Programming
Finally, a total of 77 scenarios (all possible scenarios) were pro-
grammed into the Allergy Diary Companion. The app was programmed
and designed by Peercode, Netherlands, using the digital specifica-
tions above (including expert treatment recommendations), ensuring
consideration of each possible input into the app. It was developed in
Titanium Appcelerator (JavaScript) for tablets on the IOS platform and
is easily translated and modified. Usability of the app and reliability of
the treatment recommendations it provides has been checked by
Peercode and further validation is currently ongoing prior to launch.
The app requires no Internet function after download.
3 | RESULTS
3.1 | Summary of survey results
Mean scores for each question were calculated to show the level of
consensus for each of the 34 AR CDSS scenarios (Table 1 and Fig-
ure S3A-D). Experts endorsed the AR CDSS approach, with good
agreement achieved on step‐up and step‐down treatment recom-
mendations. In summary:
• AR treatment should be stepped‐up for treated AR patients with
a VAS score ≥5/10 cm.
• For patients with VAS score ≥2 to <5/10 cm, treatment should
be continued for patients with intermittent AR (IAR) and con-
tinued or stepped‐up for those with persistent AR (PER).
• Treatment should be stepped‐down for patients with a VAS score
<2/10 cm.
• When step‐up treatment is recommended, patients on T1 should
be stepped up to T2 OR T3.
• When step‐up treatment is recommended, patients on T2 should
be stepped up to T3.
• Short course oral corticosteroids (ie T4) may be added here if
necessary.
• Patients should be referred (eg to ENT or allergy specialists) if
VAS score remains ≥ 5/10 cm or if there is a need for oral corti-
costeroids.
• When step‐up treatment is recommended, patients on multiple
therapies should be stepped up to T3 and T4 added on (short
course to minimize side-effects and only if necessary).
• Stepping‐down treatment was essentially the same in reverse,
with the proviso that patients with nasal congestion should
be stepped‐down to an INCS-containing regimen in preference
to T1 (albeit many patients will self-medicate and stop treat-
ment).**
• Treatment step-up and step-down strategies remain the same
irrespective of AIT status.*
*: Does not consider the indication of AIT.
**: Modified after expert consensus.
3.2 | Digital specification of the e‐CDSS modules
To make a treatment recommendation, the CDSS within the Allergy
Diary Companion must be “fed” with information. We have
described this information as modules (Table 2) with each of mod-
ules 1, 2 and 3 providing the input necessary for module 4 (ie
e‐CDSS).
3.2.1 | Module 1 (VAS score)
During physician consultation or pharmacist visit, patients generate a
VAS score using their finger and the touchscreen functionality of an
iPad, allowing selection of VAS score from 0 to 10 cm (inclusive).
For the purpose of the e‐CDSS, VAS scores are categorized as ≥5/
10 cm (uncontrolled AR), ≥2 to <5/10 cm (partly controlled AR) and
<2/10 cm (well‐controlled AR) (Table 2), the same as those cut‐offs
used by Allergy Diary. These cut‐offs were selected based on clinical
studies in both asthma and rhinitis.12-17
3.2.2 | Module 2 (treatment classification system)
The purpose of this module is to define the class(es) of current AR
medications used by patients. A simple alphanumeric system was
used for the e‐CDSS, with treatments classified from T0 (no treat-
ment) up to T5 (consider referral and AIT) (Table 2).
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(A)
(B)
F IGURE 2 Decision processes underlying treatment recommendations for (A) patients not currently on any AR medication, (B) patients with
well‐controlled AR (ie VAS score <2/10 cm), (C) patients with partly controlled AR (ie VAS score ≥2 to <5/10 cm) and (D) patients with uncontrolled
AR (ie VAS score ≥ 5/10 cm). AR, allergic rhinitis; VAS, visual analogue scale; M1, module 1; M2, module 2; M3, module 3; Ti, class of current
treatment (in case of polypharmacy, Ti = maximum class). Tj, Tk and Tl, medications added to Ti, order of class l < k < j < i. T1, antihistamine (oral,
intranasal and eye drops), leukotriene receptor antagonist, cromone (intranasal and eye drops); T2, intranasal corticosteroid (INCS); T3,
INCS + Azelastine; T4 add short course of oral corticosteroids; T5, consider referral and allergen‐specific immunotherapy
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(C)
(D)
F IGURE 2 Continued
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TABLE 1 KOL consensus opinion and level of agreement for each scenario of the AR CDSS
Part 1: Approach to treatment
Patient VAS (0–10 cm) Phenotype Tx Consensus Level of agreement
1 ≥5 IAR or PER Yes Step‐up 91
2 ≥2 to <5 IAR Yes Continue 76
3 <2 IAR Yes Step‐down 85
4 ≥2 to <5 PER Yes Continue or step‐up 88
5 <2 PER Yes Step‐down 75
6 ≥5 IAR No Initiate 97
7 ≥5 PER No Initiate 98
8 <5 IAR or PER No Initiate 87
Part 2: Specific treatment step‐ups
Current Tx Step‐up Notes
9 T1 T2 OR T3 91
10 T2 T3 83
11 T3 T3 + T4a Consider T5b 66
12 T1 + T2 T3 Consider T5b 80
13 T1 + T3 T3 + T4a Consider T5b 68
14 T2 + T3 T3 + T4 Consider T5b 66
15 T5 + VAS ≥5 T5 + T2 OR T3 80
16 T5 + VAS ≥2 to <5 T5 + T1, T2 OR T3 T5 + T2 or T3 if congestion 84
17 T5 + T1 T5 + T2 OR T3 89
18 T5 + T2 T5 + T3 86
19 T5 + T3 Continue Consider referral 86
Part 3: Specific treatment step‐downs
Current Tx Step‐down Notes
20 T3 T2 OR T1 T2 if congestion 78
21 T2 T1 Continue T2 if congestion 73
22 T1 Stop NOT exposed to allergen 86
23 T1 Continue EXPOSED to allergen 84
24 T1 + T2 T1 OR T2 T2 if congestion 87
25 T1 + T3 T1 OR T3 T3 if congestion 79
26 T2 + T3 T2 OR T3 87
27 T5 + T3 T5 + T1 OR T2 T5 + T2 if congestion 80
28 T5 + T2 T5 + T1 Continue T5 + T2 if congestion 75
29 T5 + T1 T5 NOT exposed to allergen 91
30 T5 + T1 T5 + T1 EXPOSED to allergen 83
31 T5 T5 Until end of course 97
Part 4: treatment initiation
Patients Tx Consensus Notes
32 IAR; VAS ≥5 No T1, T2 OR T3 T2 or T3 if congestion 83
33 PER; VAS ≥5 No T2 OR T3 90
34 IAR or PER VAS <5 No T1, T2 OR T3 T2 or T3 if congestion 87
VAS: visual analogue scale; Tx: treatment; IAR: intermittent allergic rhinitis; PER: persistent allergic rhinitis; T1: antihistamine (oral, intranasal and eye
drops), leukotriene receptor antagonist or cromones (intranasal and eye drops); T2: intranasal corticosteroids (INCS); T3: INCS + azelastine; T4: oral
corticosteroid; T5: consider referral and allergen‐specific immunotherapy; Level of agreement: VAS≥75: excellent; VAS 50‐74: good.
aShort course (3‐7 days)
bIf VAS score remains ≥5/10.
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3.2.3 | Module 3 (patient information)
Patients input this information into the Allergy Diary Companion dur-
ing physician consultation. The information gathered (or computed)
includes:
• Specific AR medication currently used
• AR phenotype (ie IAR or PER)
o AR phenotype is classified according to duration of medica-
tion use (Questions 3a and 4a, Table 2) or duration of symp-
toms for untreated patients (Questions 3b and 4b, Table 2)
• Allergen exposure status
o Information on what constitutes an allergen is provided for
patients
AR medication(s) are selected from a scrolled list of all over the
counter or prescribed medications available in each country (Ques-
tion 2a, Table 2). Multiple medication selections are permitted. For
each medication class selected, a corresponding treatment code is
assigned by the system. Exposure to allergen is assessed using a sim-
ple true or false algorithm (Table 2). Figure S4 shows the organo-
gram of the sequence of questions that patients answer in Module
3. At any step, the patient can go back to a previous question to
correct his/her answer, or cancel the survey answer. No personal
information is collected.
3.2.4 | Module 4 (e‐CDSS specifications)
The e‐CDSS uses data obtained from the other modules to deliver a
recommendation corresponding to the most appropriate treatment.
Table 2 summarizes how this information is gathered, the input used
by the e‐CDSS to make a decision and the variables used (online
Supporting information). Information from each of these modules is
used to produce treatment recommendations. The decision pro-
cesses underlying treatment recommendations are shown in Figure 2
(A‐D). Four decision processes were developed to cover 4 scenarios:
(a) the patient is not currently on any AR medication (Figure 2A), (b)
the patient has well‐controlled AR (ie VAS score <2 cm; Figure 2B),
(c) the patient has partly controlled AR (ie VAS score ≥2 to <5 cm;
Figure 2C) and (d) the patient has uncontrolled AR (ie VAS score ≥
5 cm; Figure 2D).
3.3 | Interfaces specifications
3.3.1 | Collecting information
Allergy Diary Companion screen interfaces for collecting VAS score
for the e‐CDSS is shown in Figure 3A. The VAS question is “overall
TABLE 2 Modules of e‐CDSS
Info Description e‐CDSS decision or input e‐CDSS variable
M1 VAS (0–10 cm) <2: well controlled
≥2 to <5: partly controlled
≥5: uncontrolled
<2
≥2 to <5
≥5
[1…5]
M2 Treatment classification None T0
AH/LTRA/cromone T1 Ti, Tj, Tk, Tl
INCS T2
INCS and AZE T3
OC T4
Consider referral and AIT T5
M3 Patient characteristics Q1: Do you currently take AR medication? Current med {True/false}
Q2a: Select medication(s) Scrolled list
Q3a: How many days/week do you usually take your Tx (1‐7)? Week ≥4 & day ≥4 {True/false}
True=PER
False=IAR
Q4a: How many consecutive weeks do you take it (1‐5 or more)?
Q2b: Is this the first time experiencing symptoms? First experience {True/false}
Q3b: How many days/week do they last (1‐7)? Week ≥4 & day ≥4 {True/false}
True=PER
False=IAR
Q4b: How many consecutive weeks do they last (1‐5, or more)?
Q5: Are you currently exposed to allergen? Yes or don't know {True/false}
True=yes
False=no
M4 CDSS Data from M1, M2 and M3
CDSS, clinical decision support system; VAS, visual analogue scale; AH, antihistamine (oral, intranasal and eye drops); LTRA, leukotriene receptor antago-
nist; INCS, intranasal corticosteroid; AZE, azelastine; OC, oral corticosteroid; AIT, allergen‐specific immunotherapy; AR, allergic rhinitis; Tx, treatment;
PER, persistent AR; IAR, intermittent AR; Ti, current treatment (if multiples Ti = highest medication class); Tj,k,l, add on treatments to Ti.
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how much are your allergic symptoms bothering you today?” and is
identical to that used in the Allergy Diary for patients, ensuring that
both physicians and patients are speaking the same language of AR
control. This allows for interconnectivity between applications, con-
sistency of AR control assessment and computation. The Allergy
Diary Companion screen Interfaces for collecting information on AR
medication use, AR phenotype and allergen exposure (Module 3) are
shown in Figure S5.
3.3.2 | Summarizing information
The following information is summarized by Allergy Diary Companion
for providers (Figure 3B):
• AR disease control status message: “Your patient has [well-, partly-
or un-] controlled allergic rhinitis.”
• Current VAS score of the patient: this is expressed as a positive
integer to one decimal place. AR control is categorized according
to this VAS score, and colour coded in the same way as for the
Allergy Diary—well-controlled AR: green (VAS score <2 cm); partly
controlled AR: yellow (VAS score ≥2 to <5 cm); and uncontrolled
AR: orange: (VAS score ≥5 cm) (Figure 3B).
• AR phenotype: This is categorized as either “intermittent” or
“persistent” depending on the duration of treatment (or symp-
toms).
• Allergen exposure: summarized as either “yes” or “no”
• Treatment: List of currently taken AR treatments.
3.3.3 | Treatment recommendation
A treatment recommendation is then provided based on this infor-
mation, and using the rules as outlined in the e‐CDSS (Figures 2A‐
D) and summarized in Table 1. Treatment recommendations are in
the format: Recommendation—approach—specific treatment recom-
mendation. For the example shown in Figure 3B, the recommenda-
tion is to step‐up treatment, as the patient has a VAS score ≥5/
10 cm, has IAR (with allergen exposure) and is currently treated
(with AIT and FP—ie T5 + T2)—see Table 1 scenario 1. The rec-
ommended treatment option is to continue the AIT course and
step‐up symptomatic treatment to INCS + AZE (ie step‐up from
T5 + T2 = T5 + T3)—see Table 1 scenario 18. By clicking on
“INCS + AZE,” the treatment listed is “Dymista”, currently the only
medication in this class.
4 | DISCUSSION
In this article, we describe a 21st century approach to AR manage-
ment. m‐Health refers to the use of mobile devices to collect, collate
and assess patient level health data. In this article, we focus on
CDSS and m‐health in AR and describe the process of transforming
the recently published AR CDSS2 into an e‐CDSS, and how this
e‐CDSS was embedded into an m‐health tool for providers called the
Allergy Diary Companion.
Incorporation of the e‐CDSS into the Allergy Diary Companion
was achieved in a systematic and collaborative way, by (a) generating
treatment management scenarios, (b) obtaining expert consensus on
specific AR CDSS‐informed treatment recommendations, allowing for
variations in line with expert opinion; (c) generating electronic algo-
rithms to describe all scenarios within the AR CDSS; (d) digitizing
these algorithms to form the e‐CDSS; and finally (e) embedding the
e‐CDSS into the Allergy Diary Companion app to permit easy user
interfacing. In this way, the Allergy Diary Companion serves as a
knowledge translation intervention for providers, a dynamic and iter-
ative process that induces the synthesis, dissemination, exchange
and ethically sound application of knowledge to improve health,18
encouraging change in behaviour in keeping with scientific evidence.
Key experts in the field of AR from all over the world agreed on the
AR CDSS approach to AR management and on specific treatment
recommendations provided by Allergy Diary Companion and informed
by VAS score, disease phenotype, allergen exposure and treatment
history. To our knowledge, this is the first time the development of
any m‐health tool has been described in this transparent and
detailed way, providing confidence, not only in the app, but also in
the treatment recommendations it provides.
The Allergy Diary Companion is essentially a decision aid for pro-
viders. Decision aids increase knowledge, reduce decisional conflict
and have a positive effect on patient‐practitioner communication
19,20 and may be particularly effective when incorporated into an e‐
health tool. For example, when providers use handheld computers to
access clinical information, their knowledge improves significantly
more than peers who use paper resources. Physician adherence to
guidelines is poor21 and it is hoped that when guideline recommen-
dations are presented electronically, providers may make safer pre-
scribing decisions and adhere more closely to these
recommendations vs peers using paper resources.22 Unfortunately,
at the physician level CDSSs are rarely used, and the advice is not
followed,23 even though use of computerized CDSSs have been
shown to improve asthma and COPD care.24 Embedding the AR
CDSS into the Allergy Diary Companion is expected to increase usage
of the AR CDSS, resulting in improved standard of AR care in rou-
tine clinical practice, both at the physician and pharmacy levels.
Indeed, CDSSs have already proved beneficial at the pharmacy
level,25,26 reducing the frequency of drug‐drug interactions and pre-
venting inappropriate prescribing and underprescribing.27 It should
also be noted that although a recently conducted Cochrane review
provided no evidence that the use of electronic health information
(EHI) translates into improved clinical practice or patient outcomes,
it does suggest that when practitioners are provided with EHI and
education or training, its use increases.28 It was further noted that
for EHI to be applied in patient care, it will be necessary to under-
stand why practitioners’ are reluctant to apply EHI when treating
people and to determine the most effective way(s) to reduce this
reluctance.28
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F IGURE 3 (A) VAS interface of Allergy Diary and Allergy Diary Companion apps and (B) treatment recommendation provided by e‐CDSS of
the Allergy Diary Companion app, including information from Modules 1, 2 and 3
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On the patient side, mobile phone apps to improve allergy and
asthma care are part of an ever‐growing number of m‐tools available,
but their usefulness is still debated and studies have been small.29,30
However, a large study including 327 individuals with AR or asthma,
showed that QoL was improved in AR patients and the likelihood of
asthma control increased when using an app which facilitated com-
munication with physicians and which recorded health status and
medication compliance.31
A limitation of the Allergy Diary Companion is that it currently
relies on the input of information by patients themselves. It does not
take into account data already recorded by patients in their Allergy
Diary. In other words, there is a lack of connectivity between
m‐health tools. One improvement could be to upload patient data
directly from the Allergy Diary to the Allergy Diary Companion (ie
Module 5; see Figure 4). This step would need serious ethical con-
sideration that is currently being discussed. Personal data protection
is a fundamental right in Europe, enshrined in Article 8 of the Char-
ter of Fundamental Rights of the European Union, as well as in Arti-
cle 16(1) of the Treaty on the Functioning of the European Union.
Guidance already exists on data protection requirements for “apps”
with Opinion 2/2013 of the Article 29 Working Party of 27 February
2013 on apps on smart devices. In the EU, the currently applicable
Personal Data Protection Directive is being revised in order to better
respond to challenges posed by the rapid development of new tech-
nologies and globalization while ensuring that individuals retain
effective control over their personal data. The Allergy Diary Compan-
ion app will comply with all local and European directives. Future
iterations of the Allergy Diary Companion may permit connectivity
with pollen, air pollution, meteorologic storm warnings and Google
Trends which may influence treatment recommendations. Finally, all
Allergy Diary Companion app functionally and management advice
needs to be validated, and this will be done prior to launch. The
Allergy Diary Companion app is an ideal tool to assess the benefit of
using the AR CDSS in a real‐life setting. The value of this m‐health
tool is that it allows for variations and modifications of the e‐CDSS
based on real‐life experience, thus moving from a consensus‐based
CDSS to an evidence‐based one.
Other modules which may be used to “feed” the e‐CDSS could
include identification of those patients at risk of allergen exposure
by incorporating a pollen alert module (Module 6; Figure 4) and a
sentinel network module (Module 7; Figure 4). The sentinel network
is an early warning system or predictor for patients of impending
symptoms. A recently obtained H2020 grant (POLLAR: Impact of air
pollution in asthma and rhinitis) will help to answer this question.
This system should also prove useful in predicting asthma control
deterioration in those with comorbid rhinitis. Use of predictive algo-
rithms have already been used in home monitoring of asthma and
chronic obstructive pulmonary disease patients, but with varying
degrees of success, mainly due to poor patient compliance and poor
performance of conventional algorithms for detecting deteriora-
tions.32 These improvements to the system would essentially negate
the need for Modules 1 and 3 for those users with smartphones.
Modules 1 and 3 would remain in the system for those patients who
do not have a smartphone or do not wish to download Allergy Diary.
Finally, a PC‐based tool should also be developed, enabling physi-
cians to import data, with individual patient consent, to their pc
directly from the patient's Allergy Diary, interacting with Allergy Diary
Companion, so that data may be stored as an electronic file as part
of the patient's notes.
When developing any new m‐health tool, the aim is to achieve
a high quality and popular app, which will be used enthusiastically
and provide benefit to users. This is a challenging process, and not
F IGURE 4 Schematic representation of
architecture of an improved e‐CDSS. M,
module; Tx, treatment; e‐CDSS, electronic
clinical decision support system
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always entirely successful, either due to design issues33 or at the
implementation stage.28,34 Allergy Diary Companion for providers
has been designed to be used in conjunction with the Allergy Diary
for patients as part of MASK (included in the B3 action plan of the
European Innovation Partnership on Active and Healthy Ageing
(EIA on AHA)). MASK follows the JA‐CHRODIS (Joint Action on
Chronic Diseases and Promoting Healthy Ageing across the Life
Cycle) recommendations for the evaluation of good practices. This
means that it works well, produces good results and is recom-
mended as a model.35 MASK complies with equity (design and
implementation), practice (eg appropriateness of design and SMART
objectives), ethical, evaluation, empowerment/participation, target
population, sustainability, governance and scalability targets.35 Use
of both apps will (a) permit patients to screen for allergic disease
and monitor AR and asthma control, (b) assist pharmacists in rec-
ommending over the counter medications and prompt referral of
patients with uncontrolled AR to physicians and (c) encourage pri-
mary care physicians to prescribe appropriate treatment, to follow‐
up in accordance with the AR CDSS and to refer to specialist clin-
ics when appropriate.36 However, the e‐CDSS does not include
information on allergic multimorbidities.37 That will be included at a
later stage.
In conclusion, the Allergy Diary Companion for providers has been
designed to provide healthcare information to practitioners and
researchers, to permit real‐time monitoring of disease‐related data
and to provide guideline and expert‐endorsed AR treatment recom-
mendations. The Allergy Diary Companion is currently being finalized
and will be launched in 2018.
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